GAIN THERAPEUTICS INC's ticker is GANX and the CUSIP is 36269B105. A total of 25 filers reported holding GAIN THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.73 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,448,589 | -7.1% | 546,560 | 0.0% | 0.12% | -19.6% |
| Q1 2023 | $2,634,419 | +54.0% | 546,560 | 0.0% | 0.14% | +21.2% |
| Q4 2022 | $1,710,732 | -3.9% | 546,560 | 0.0% | 0.12% | -6.3% |
| Q3 2022 | $1,781,000 | -9.5% | 546,560 | 0.0% | 0.13% | -17.6% |
| Q2 2022 | $1,967,000 | -12.0% | 546,560 | 0.0% | 0.15% | +7.7% |
| Q1 2022 | $2,236,000 | -24.7% | 546,560 | 0.0% | 0.14% | -16.5% |
| Q4 2021 | $2,968,000 | -27.1% | 546,560 | 0.0% | 0.17% | -37.7% |
| Q3 2021 | $4,069,000 | -25.6% | 546,560 | 0.0% | 0.27% | -20.4% |
| Q2 2021 | $5,466,000 | -33.0% | 546,560 | 0.0% | 0.34% | -39.6% |
| Q1 2021 | $8,155,000 | – | 546,560 | – | 0.57% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 90,000 | $403 | 0.39% |
| Greenlight Capital | 546,560 | $2,448,589 | 0.12% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 58,100 | $260,288 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 46,100 | $206,528 | 0.01% |
| NewEdge Advisors, LLC | 11,050 | $49,504 | 0.00% |
| Tower Research Capital LLC (TRC) | 4,347 | $19,475 | 0.00% |
| MILLENNIUM MANAGEMENT LLC | 12,562 | $56,278 | 0.00% |
| Citadel Advisors | 16,900 | $75,712 | 0.00% |
| Citadel Advisors | 36,247 | $162,387 | 0.00% |
| MORGAN STANLEY | 800 | $3,584 | 0.00% |